Turbo cancers

Since the start of the Covid-19 pandemic, there have been increasing numbers of cases of a rapid, aggressive onset of cancer in individuals who were previously healthy, in remission, or without prior cancer diagnoses.Turbo cancers are being described as malignancies that manifest and metastasize within days, weeks, or a few months of first detection. These cancers develop far faster than conventional tumor growth patterns. Not only do these cancers display unexpected severity, they also seem to respond poorly to treatment. Another factor that seems to set them apart is their demographic profile. Otherwise healthy individuals, often much younger than expected, with no significant risk factors, present signs of this rapidly fatal disease shortly after an immune-triggering event such as SARS-CoV-2 infection or an mRNA COVID vaccination.

Although turbo cancer is not a formally recognized medical classification, such as the ICD-10 or the World Health Organization's oncology taxonomies, the term has been increasingly used to characterize a distinct clinical pattern cancers observed since the onset of the pandemic and the widespread rollout of mRNA-based vaccines. 

Turbo cancer cases often appear shortly after immune system activation, which suggests a probable immunological or inflammatory mechanism. Some hypotheses are being proposed including impaired T-cell and/or NK-cell surveillance, persistent cytokine signals and stress-induced oncogenesis.

Between 2022 and 2024, a marked and concerning rise in cancer incidence has been documented across numerous peer-reviewed studies with a mounting evidence that this trend may be linked to exposures unique to the SARS-CoV-2 virus and the widespread administration of mRNA vaccines produced by Pfizer-BioNTech and Moderna. These increases are not only significant in magnitude but also alarming in the demographics affected. Cancers are increasingly diagnosed in younger adults. This trend deviates sharply from historical baselines. Data from the UK, for instance, revealed a 6.7% rise in breast cancer diagnoses in 2022, particularly among women under 50. In Canada, breast cancer diagnoses rose by 13% and colorectal cancers by 8% in 2022. Younger adults aged between 20-39 well surpassed pre-pandemic levels. The US SEER registry and CDC data also report an accelerated increase in cancer incidence since 2021, especially among individuals aged 20-39 with overall rates growing 1.15% annually since 2005 but the rising more dramatically post-2020.. Similarly, a large Nordic registry analysis identified a significant increase in advanced-Stage III-IV cancers in 2021-2022 following diagnostic delays in 2020. Breast, lung, and colorectal cancers sharply exceeded pre-pandemic levels. Finally, a Polish cohort study covering 3.5 million individuals reported a similar surge in late-stage breast, head and neck, and colorectal cancers by late 2022.

Importantly, these alarming rebounds are not confined to high-risk or elderly populations but are disproportionately impacting younger cohorts who traditionally face lower cancer risk. In the US, men aged 30-50 are experiencing the sharpest increases in head and neck cancers. Furthermore, a study analyzing Google Trends identified a surge in public internet searches for cancer symptoms beginning in 2022. This very likely reflects a very real increase in symptom burden or a rapid inexplicable onset of the disease. This trend is being most observed in highly vaccinated nations with otherwise robust healthcare access. While the medical establishment's and government health agencies' explanations center around disrupted screening and delayed diagnosis, the continued rise in cancer cases--despite the official end of the pandemic--suggests the involvement of far more insidious biological drivers. The only globally ubiquitous novel exposures during this time were SARS-CoV-2 viral infections and the unprecedented deployment of mRNA vaccine platforms, which operate through systemic lipid nanoparticle delivery and synthetic RNA constructs that are capable of modifying host immune responses for unknown time durations.